Aldosterone and the heart: Still an unresolved issue?

Frontiers in Endocrinology

Volumn 5, Issue OCT, 2014, Pages

  Catena, Cristiana ^a   Colussi, GianLuca ^a   Nait, Francesca ^a   Martinis, Flavia ^a   Pezzutto, Francesca ^a   Sechi, Leonardo A ^a  

^a UNIVERSITY HOSPITAL OF UDINE   (Italy)

Author keywords

Adrenalectomy; Aldosterone; Aldosterone producing adenoma; Bilateral adrenal hyperplasia; Echocardiography; Left ventricular hypertrophy; Left ventricular mass; Mineralocorticoid receptor antagonists

Indexed keywords

ALDOSTERONE; ANGIOTENSIN II; ENALAPRIL; INWARDLY RECTIFYING POTASSIUM CHANNEL; LARGE CONDUCTANCE CALCIUM ACTIVATED POTASSIUM CHANNEL; MINERALOCORTICOID; MINERALOCORTICOID ANTAGONIST; REACTIVE OXYGEN METABOLITE; SPIRONOLACTONE;

ALDOSTERONE BLOOD LEVEL; CARDITIS; HEART FUNCTION; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE MASS; HEART MUSCLE FIBROSIS; HEART MUSCLE INJURY; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; OXIDATIVE STRESS; PRIMARY HYPERALDOSTERONISM; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SHORT SURVEY; TISSUE INJURY;

EID: 84949134824     PISSN: None     EISSN: 16642392     Source Type: Journal    
DOI: 10.3389/fendo.2014.00168     Document Type: Short Survey

References (53)

1. Lombes M, Alfaidy N, Eugene E, Lessana A, Farman A, Bonvalet JP. Prerequisite for cardiac aldosterone action: mineralocorticoid receptor and 11-ß-hydroxysteroid dehydrogenase in the human heart. Circulation (1995) 92:175-82. doi:10.1161/01.CIR.92.2.175
2. Marney AM, Brown NJ. Aldosterone and end-organ damage. Clin Sci (2007) 113:267-8. doi:10.1042/CS20070123
3. Rocha R, Rudolph AE, Frierdich GE, Nachowiak DA, Kekec BK, Blomme EA, et al. Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol (2002) 283:H1802-10.
4. Brilla CG, Weber KT. Mineralocorticoid excess, dietary sodium, and myocardial fibrosis. J Lab Clin Med (1992) 120:893-901.
5. Martinez DV, Rocha R, Matsumura M, Oestreicher E, Ochoa-Maya M, Roubsanthisuk W, et al. Cardiac damage prevention by eplerenone: comparison with low sodium diet or potassium loading. Hypertension (2002) 39:614-8.
6. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med (1999) 341:709-17. doi:10.1056/NEJM199909023411001
7. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med (2003) 348:1309-21. doi:10.1056/NEJMoa030207
8. Zannad F, McMurray JJV, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med (2011) 364:11-21. doi:10.1056/NEJMoa1009492
9. He BJ, Joiner ML, Singh MV, Lukzak ED, Swaminathan PD, Koval OM, et al. Oxidation of CaMKII determines the cardiotoxic effects of aldosterone. Nat Med (2011) 17:1610-8. doi:10.1038/nm.2506
10. Mohammed SF, Ohatani T, Korinek J, Lam CS, Larsen K, Simari RD, et al. Mineralocorticoid accelerates transition to heart failure with preserved ejection fraction via "nongenomic" effects. Circulation (2010) 122:378-9. doi:10.1161/CIRCULATIONAHA.109.915215
11. Ohtani T, Ohta M, Yamamoto K, Mano T, Sakata Y, Nishio M, et al. Elevated cardiac tissue level of aldosterone and mineralocorticoid receptor in diastolic heart failure: beneficial effects of mineralocorticoid receptor blocker. Am J Physiol Regul Integr Comp Physiol (2007) 292:R954-64.
12. Kobayashi N, Yoshida K, Nakano S, Ohno T, Honda T, Tsubokou Y, et al. Cardioprotective mechanisms of eplerenone on cardiac performance and remodeling in failing rat hearts. Hypertension (2006) 47:671-9. doi:10.1161/01.HYP.0000203148.42892.7a
13. Stas S, Whaley-Connell A, Habibi J, Appesh L, Hayden MR, Karuparthi PR, et al. Mineralocorticoid receptor blockade attenuates chronic overexpression of the renin-angiotensin-aldosterone system stimulation of NADPH oxidase and cardiac remodeling. Endocrinology (2007) 148:3773-80. doi:10.1210/en.2006-1691
14. Fraccarollo D, Berger S, Galuppo P, Kneitz S, Hein L, Schutz G, et al. Deletion of cardiomyocyte mineralocorticoid receptor ameliorates adverse remodeling after myocardial infarction. Circulation (2011) 123:400-8. doi:10.1161/CIRCULATIONAHA.110.983023
15. Habibi J, De Marco VG, Ma L, Pulakat L, Rainey WE, Whaley-Connell AT, et al. Mineralocorticoid receptor blockade improve diastolic function independent of blood pressure reduction in a transgenic model of RAAS overexpression. Am J Physiol Heart Circ Physiol (2002) 300:H1484-91. doi:10.1152/ajpheart.01000.2010
16. Mihailidou AS, Bundgaard H, Mardini M, Hansen PS, Kjeldsen K, Rasmussen HH. Hyperaldosteronemia in rabbits inhibits the sarcolemmal Na(+)-K(+) pump. Circ Res (2000) 86:37-42. doi:10.1161/01.RES.86.1.37
17. Muto T, Ueda N, Opthof T, Ohkusa T, Nagata K, Suzuki S, et al. Aldosterone modulates I(f) current through gene expression in cultured neonatal rat ventricular myocytes. Am J Physiol (2007) 293:H2710-8.
18. Lacolley P, Labat C, Pujol A, Delcayre C, Benetos A, Safar M. Increased carotid wall elastic modulus and fibronectin in aldosterone-salt treated rats: effects of eplerenone. Circulation (2002) 106:2848-53. doi:10.1161/01.CIR.0000039328.33137.6C
19. Neves MF, Amiri F, Virdis A, Diep QN, Schiffrin EL. CIHR Multidisciplinary Research Group on Hypertension. Role of aldosterone in angiotensin II-induced cardiac and aortic inflammation, fibrosis, and hypertrophy. Can J Physiol Pharmacol (2005) 83:999-1006. doi:10.1139/y05-068
20. Cachofeiro V, Miana M, de Las Heras N, Martín-Fernández B, Ballesteros S, Fernández Tresguerres J, et al. Aldosterone and the vascular system. J Steroid Biochem Mol Biol (2008) 109:331-5. doi:10.1016/j.jsbmb.2008.03.005
21. Jaffe IZ, Mendelsohn ME. Angiotensin II and aldosterone regulate gene transcription via functional mineralocorticoid receptors in human coronary artery smooth muscle cell. Circ Res (2005) 96:643-50. doi:10.1161/01.RES.0000159937.05502.d1
22. Nguyen Dinh Cat A, Griol Charhbili V, Loufrani L, Labat C, Benjamin L, Farman N, et al. The endothelial mineralocorticoid receptor regulates vasoconstrictor tone and blood pressure. FASEB J (2010) 24:2454-63. doi:10.1096/fj.09-147926
23. Benard L, Milliez P, Ambroisine ML, Messaoudi S, Samuel JL, Delcayre C. Effects of aldosterone on coronary function. Pharmacol Rep (2009) 61:58-66. doi:10.1016/S1734-1140(09)70007-6
24. Favre J, Gao J, Zhang AD, Remy-Jouet I, Ouvrard-Pascaud A, Dautreaux B, et al. Coronary endothelial dysfunction after cardiomyocyte - specific mineralocorticoid receptor overexpression. Am J Physiol Heart Circ Physiol (2011) 300:H2035-43. doi:10.1152/ajpheart.00552.2010
25. Frohlich ED. Left ventricular hypertrophy: an independent risk factor. Cardiovasc Clin (1990) 20:85-94.
26. Devereux RB, Wachtell K, Gerdts E, Boman K, Nieminen MS, Papademetriou V, et al. Prognostic significance of left ventricular mass change during treatment in hypertension. JAMA (2004) 292:2350-6. doi:10.1001/jama.292.19.2350
27. Schmieder RE, Martus P, Klingbeil A. Reversal of left ventricular hypertrophy in hypertension: a metaanalysis of randomized double-blind studies. JAMA (1996) 275:1507-13. doi:10.1001/jama.1996.03530430051039
28. Cuspidi C, Negri F, Zanchetti A. Angiotensin II receptor blockers and cardiovascular protection: focus on left ventricular hypertrophy regression and atrial fibrillation prevention. Vasc Health Risk Manag (2008) 4:67-73. doi:10.2147/vhrm.2008.04.01.67
29. Staessen J, Lijnen P, Fagard R, Verschueren LJ, Amery A. Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. J Endocrinol (1981) 91:457-65. doi:10.1677/joe.0.0910457
30. Sato A, Saruta T. Aldosterone escape during angiotensin-conveting enzyme inhibitor therapy in essential hypertensive patients with left ventricular hypertrophy. J Int Med Res (2001) 29:13-21. doi:10.1177/147323000102900103
31. Sato A, Hayashi M, Saruta T. Relative long-term effects of spironolactone in conjunction with an angiotensin-converting enzyme inhibitor on left ventricular mass and diastolic function in patients with essential hypertension. Hypertens Res (2002) 25:837-42. doi:10.1291/hypres.25.837
32. Taniguchi I, Kawai M, Date T, Yoshida S, Seki S, Taniguchi M, et al. Effects of spironolactone during an angiotensin II receptor blocker treatment on the left ventricular mass reduction in hypertensive patients with concentric left ventricular hypertrophy. Circ J (2006) 70:995-1000. doi:10.1253/circj.70.995
33. Pitt B, Reichek N, Willenbrock R, Zannad F, Phillips RA, Roniker B, et al. Effects of eplerenone, enalalpril, and eplerenone/enelapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation (2003) 108:1831-8. doi:10.1161/01.CIR.0000091405.00772.6E
34. Mottram PM, Haluska B, Leano R, Cowley D, Stowasser M, Marwick TH. Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure. Circulation (2004) 110:558-65. doi:10.1161/01.CIR.0000138680.89536.A9
35. Gaddam K, Corros C, Pimenta E, Ahmed M, Denney T, Aban I, et al. Rapid reversal of left ventricular hypertrophy and intracardiac volume overload in patients with resistant hypertension and hyperaldosteronism: a prospective clinical study. Hypertension (2010) 55:1137-42. doi:10.1161/HYPERTENSIONAHA.109.141531
36. Sechi LA, Colussi GL, Catena C. Hyperaldosteronism and left ventricular hypertrophy. Hypertension (2010) 56:e26. doi:10.1161/HYPERTENSIONAHA.110.156273
37. Conn JW, Knopf RF, Nesbit RM. Clinical characteristics of primary aldosteronism from an analysis of 145 cases. Am J Surg (1964) 107:159-72. doi:10.1016/0002-9610(64)90252-1
38. Laragh JH. Vasoconstriction-volume analysis for understanding and treating hypertension: the use of renin and aldosterone profiles. Am J Med (1973) 55:261-74. doi:10.1016/0002-9343(73)90128-9
39. Sechi LA, Colussi GL, Di Fabio A, Catena C. Cardiovascular and renal damage in primary aldosteronism: outcomes after treatment. Am J Hypertens (2010) 23:1253-60. doi:10.1038/ajh.2010.169
40. Catena C, Colussi G, Marzano L, Sechi LA. Aldosterone and the heart: from basic research to clinical evidence. Horm Metab Res (2012) 44:181-7. doi:10.1055/s-0031-1291318
41. Catena C, Colussi GL, Marzano L, Sechi LA. Predictive factors of left ventricular mass changes after treatment of primary aldosteronism. Horm Metab Res (2012) 44:188-93. doi:10.1055/s-0032-1301902
42. Muiesan ML, Salvetti M, Paini A, Agabiti-Rosei C, Monteduro C, Galbassini G, et al. Inappropriate left ventricular mass in patients with primary aldosteronism. Hypertension (2008) 52:529-34. doi:10.1161/HYPERTENSIONAHA.108.114140
43. Rossi GP, Di Bello V, Ganzaroli C, Sacchetto A, Cesari M, Bertini A, et al. Excess aldosterone is associated with alterations of myocardial texture in primary aldosteronism. Hypertension (2002) 40:23-7. doi:10.1161/01.HYP.0000023182.68420.EB
44. Catena C, Colussi GL, Di Fabio A, Valeri M, Marzano L, Uzzau A, et al. Mineralcorticoid antagonists versus surgery in primary aldosteronism. Horm Metab Res (2010) 42:440-5. doi:10.1055/s-0029-1246185
45. Catena C, Colussi G, Lapenna R, Nadalini E, Chiuch A, Gianfagna P, et al. Long-term cardiac effects of adrenalectomy or mineralocorticoid antagonists in patients with primary aldosteronism. Hypertension (2007) 50:911-8. doi:10.1161/HYPERTENSIONAHA.107.095448
46. Rossi GP, Cesari M, Cuspidi C, Maiolino G, Cicala MV, Bisogni V, et al. Long-term control of arterial hypertension and regression of left ventricular hypertrophy with treatment of primary aldosteronism. Hypertension (2013) 62:62-9. doi:10.1161/HYPERTENSIONAHA.113.01316
47. Giacchetti G, Ronconi V, Turchi F, Agostinelli L, Mantero F, Rilli S, et al. Aldosterone as a key mediator of the cardiometabolic syndrome in primary aldosteronism: an observational study. J Hypertens (2007) 25:177-86. doi:10.1097/HJH.0b013e3280108e6f
48. Bernini G, Bacca A, Carli V, Carrara D, Materazzi G, Berti P, et al. Cardiovascular changes in patients with primary aldosteronism after surgical or medical treatment. J Endocrinol Invest (2012) 35:274-80. doi:10.3275/7611
49. Rossi GP, Cesari M, Letizia C, Seccia TM, Cicala MV, Zinnamosca L, et al. KCNJ5 gene somatic mutations affect remodelling but do not preclude cure of high blood pressure and regression of left ventricular hypertrophy in primary aldosteronism. J Hypertens (2014) 32:1514-22. doi:10.1097/HJH.0000000000000186
50. Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol (2005) 45:1243-8. doi:10.1016/j.jacc.2005.01.015
51. Catena C, Colussi G, Nadalini E, Chiuch A, Baroselli S, Lapenna R, et al. Cardiovascular outcomes in patients with primary aldosteronism after treatment. Arch Intern Med (2008) 168:80-5. doi:10.1001/archinternmed.2007.33
52. Born-Frontsberg E, Reincke M, Rump LC, Hahner S, Diederich S, Lorenz R, et al. Participants of the German Conn's Registry. Cardiovascular and cerebrovascular comorbidities of hypokalemic and normokalemic primary aldosteronism: results of the German Conn's Registry. J Clin Endocrinol Metab (2009) 94:1125-30. doi:10.1210/jc.2008-2116
53. Mulatero P, Monticone S, Bertello C, Viola A, Tizzani D, Iannaccone A, et al. Long-term cardio- and cerebro-vascular events in patients with primary aldosteronism. J Clin Endocrinol Metab (2013) 98:4826-33. doi:10.1210/jc.2013-2805